Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.

[1]  D. Murrell,et al.  A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. , 2011, Journal of the American Academy of Dermatology.

[2]  L. Strowd,et al.  Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission. , 2011, Journal of the American Academy of Dermatology.

[3]  R. Eming,et al.  Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. , 2009, The Journal of investigative dermatology.

[4]  H. Shimizu,et al.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus. , 2009, Journal of the American Academy of Dermatology.

[5]  D. Keskin,et al.  A review of the current use of rituximab in autoimmune diseases. , 2009, International immunopharmacology.

[6]  L. Borradori,et al.  Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. , 2008, The Journal of investigative dermatology.

[7]  J. Roujeau,et al.  B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. , 2008, The Journal of investigative dermatology.

[8]  T. Nishikawa,et al.  Anti‐desmoglein IgG autoantibodies in patients with pemphigus in remission , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[10]  E. Bröcker,et al.  Rituximab in Treatment-Resistant Autoimmune Blistering Skin Disorders , 2008, Clinical reviews in allergy & immunology.

[11]  B. Thiers.  A Single Cycle of Rituximab for the Treatment of Severe Pemphigus , 2008 .

[12]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[13]  R. Corona,et al.  Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. , 2007, Archives of dermatology.

[14]  L. Cavacini,et al.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.

[15]  R. Paus,et al.  Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'? , 2006, Experimental Dermatology.

[16]  M. Amagai.  Desmoglein as a target in autoimmunity and infection. , 2003, Journal of the American Academy of Dermatology.

[17]  E. Ruocco,et al.  Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. , 2002, Archives of dermatology.

[18]  T. Nishikawa,et al.  Monitoring disease activity in pemphigus with enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 , 2002, The British journal of dermatology.

[19]  P. Seed,et al.  The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels , 2001, The British journal of dermatology.

[20]  T. Nishikawa,et al.  The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. , 1999, Journal of the American Academy of Dermatology.

[21]  Komai,et al.  Usefulness of enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus , 1999, The British journal of dermatology.

[22]  J. Bystryn,et al.  Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. , 1997, Journal of the American Academy of Dermatology.

[23]  A. Ahmed,et al.  Influence of treatment on the clinical course of pemphigus vulgaris. , 1996, Journal of the American Academy of Dermatology.

[24]  J. Bystryn,et al.  The adjuvant therapy of pemphigus. An update. , 1996, Archives of dermatology.

[25]  J. Thivolet,et al.  Weaning of systemic steroid treatment in pemphigus : a twelve-year retrospective study on 270 French patients , 1995 .

[26]  J. Stanley.  Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. , 1993, Advances in immunology.

[27]  J. Stanley.  Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. , 1989, The Journal of clinical investigation.

[28]  J. Bystryn.  Adjuvant therapy of pemphigus. , 1984, Archives of dermatology.

[29]  W. F. Lever.  Pemphigus and pemphigoid: A review of the advances made since 1964 , 1979 .